Citation： 陳潔, 呂青. 《中國晚期乳腺癌診治專家共識》2015版要點解讀. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2016, 23(9): 1029-1036. doi: 10.7507/1007-9424.20160268 Copy
Copyright ? the editorial department of CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY of West China Medical Publisher. All rights reserved
| 1. | Fan L, Strasser-Weippl K, Li JJ, et al. Breast cancer in China. Lancet Oncol, 2014, 15(7):e279-e289. |
| 2. | NCCN. NCCN clinical practice guidelines in oncology:breast cancer. https://www.nccn.org/professionals/physician_gls/f_guidelines.aspbreast.. |
| 3. | Coates AS, Winer EP, Goldhirsch A, et al. Tailoring therapies-improving the management of early breast cancer:St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol, 2015, 26(8):1533-1546. |
| 4. | NIH consensus conference. Treatment of early-stage breast cancer. JAMA, 1991, 265(3):391. |
| 5. | 徐兵河.中國晚期乳腺癌診治專家共識.北京:人民衛生出版社, 2015:1-55. |
| 6. | 葉蓓, 柳光宇, 陸勁松, 等.常用的乳腺癌血清腫瘤標志物在早期診斷中的應用價值不高.中國癌癥雜志, 2009, 19(10):807-808. |
| 7. | Rosen EL, Eubank WB, Mankoff DA. FDG PET, PET/CT, and breast cancer imaging. Radiographics, 2007, 27 Suppl 1:S215-S229. |
| 8. | Eubank WB, Mankoff D, Bhattacharya M, et al. Impact of FDG PET on defining the extent of disease and on the treatment of patients with recurrent or metastatic breast cancer. AJR Am J Roentgenol, 2004, 183(2):479-486. |
| 9. | Brooks AL. From cell to organism:the need for multiparametric assessment of exposure and biological effects. 2014-12-10. http://www.birpublications.org/doi/abs/10.1259/bjr/78464782.. |
| 10. | Popp HD, Meyer M, Brendel S, et al. Leukocyte DNA damage after reduced and conventional absorbed radiation doses using 3rd generation dual-source CT technology. Eur J Radiol Open, 2016, 3:134-137. |
| 11. | Theriault RL, Carlson RW, Allred C, et al. Breast cancer, version 3.2013:featured updates to the NCCN guidelines. J Natl Compr Canc Netw, 2013, 11(7):753-760. |
| 12. | Harbeck N, Scharl A, Thomssen C, et al. AGO recommendations for diagnosis and treatment of patients with advanced and metastatic breast cancer:update 2013. Breast Care (Basel), 2013, 8(3):181-185. |
| 13. | Danna EA, Sinha P, Gilbert M, et al. Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease. Cancer Res, 2004, 64(6):2205-2211. |
| 14. | Norton L, Massagué J. Is cancer a disease of self-seeding?. Nat Med, 2006, 12(8):875-878. |
| 15. | Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med, 2004, 351(8):781-791. |
| 16. | Arriagada R, Rutqvist LE, Mattsson A, et al. Adequate locoregional treatment for early breast cancer may prevent secondary dissemination. J Clin Oncol, 1995, 13(12):2869-2878. |
| 17. | Goldie JH, Coldman A. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep, 1980, 63(11-12):1727-1733. |
| 18. | Fisher B, Gunduz N, Coyle J, et al. Presence of a growth-stimulating factor in serum following primary tumor removal in mice. Cancer Res, 1989, 49(8):1996-2001. |
| 19. | O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin:a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell, 1994, 79(2):315-328. |
| 20. | Gunduz N, Fisher B, Saffer EA. Effect of surgical removal on the growth and kinetics of residual tumor. Cancer Res, 1979, 39(10):3861-3865. |
| 21. | Salo M. Effects of anaesthesia and surgery on the immune response. Acta Anaesthesiol Scand, 1992, 36(3):201-220. |
| 22. | Dominici L, Najita J, Hughes M, et al. Surgery of the primary tumor does not improve survival in stage Ⅳ breast cancer. Breast Cancer Res Treat, 2011, 129(2):459-465. |
| 23. | Neuman HB, Morrogh M, Gonen M, et al. Stage Ⅳ breast cancer in the era of targeted therapy:does surgery of the primary tumor matter?. Cancer, 2010, 116(5):1226-1233. |
| 24. | Rapiti E, Verkooijen HM, Vlastos G, et al. Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis. J Clin Oncol, 2006, 24(18):2743-2749. |
| 25. | Hartmann S, Reimer T, Gerber B, et al. Primary metastatic breast cancer:the impact of locoregional therapy. Breast Care (Basel), 2014, 9(1):23-28. |
| 26. | Harris E, Barry M, Kell MR. Meta-analysis to determine if surgical resection of the primary tumour in the setting of stage Ⅳ breast cancer impacts on survival. Ann Surg Oncol, 2013, 20(9):2828-2834. |
| 27. | Clinicaltrials. https://clinicaltrials.gov/ct2/show/NCT00193778.. |
| 28. | Clinicaltrials. https://clinicaltrials.gov/ct2/show/NCT00557986?term=NCT00557986&rank=1.. |
| 29. | Clinicaltrials. https://clinicaltrials.gov/ct2/show/NCT01242800?term=NCT01242800&rank=1.. |
| 30. | Clinicaltrials. https://clinicaltrials.gov/ct2/show/NCT01392586?term=NCT01392586&rank=1.. |
| 31. | Clinicaltrials. https://clinicaltrials.gov/ct2/show/NCT01015625?term=NCT01015625&rank=1.. |
| 32. | Shien T, Nakamura K, Shibata T, et al. A randomized controlled trial comparing primary tumour resection plus systemic therapy with systemic therapy alone in metastatic breast cancer (PRIM-BC):Japan Clinical Oncology Group Study JCOG1017. Jpn J Clin Oncol, 2012, 42(10):970-973. |
| 33. | Badwe R, Hawaldar R, Nair N, et al. Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer:an open-label randomised controlled trial. Lancet Oncol, 2015, 16(13):1380-1388. |
| 34. | King TA, Lyman JP, Gonen M, et al. Prognostic impact of 21-gene recurrence score in patients with stage Ⅳ breast cancer:TBCRC 013. J Clin Oncol, 2016, 34(20):2359-2365. |
| 35. | ASC University. A randomized controlled trial evaluating resection of the primary breast tumor in women presenting with de novo stage Ⅳ breast cancer:Turkish Study (Protocol MF07-01). http://meeting-library.asco.org/content/170268-176.. |
| 36. | Headon H, Wazir U, Kasem A, et al. Surgical treatment of the primary tumour improves the overall survival in patients with metastatic breast cancer:a systematic review and meta-analysis. Mol Clin Oncol, 2016, 4(5):863-867. |
| 37. | Niveen A, Abo-Touk, Amir A, et al. The benefit of locoregional surgical intervention in metastatic breast cancer at initial presentation. Cancer Res J, 2016, 4(2):32-36. |
| 38. | 江澤飛, 李健斌.精準醫學時代乳腺外科十個熱點問題思考.中華普外科手術學雜志:電子版, 2016, 10(3):192-196. |
| 39. | Viale G, Regan MM, Maiorano E, et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer:BIG 1-98. J Clin Oncol, 2007, 25(25):3846-3852. |
| 40. | Allred DC. Commentary:hormone receptor testing in breast cancer:a distress signal from Canada. Oncologist, 2008, 13(11):1134-1136. |
| 41. | Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med, 2012, 366(6):520-529. |
| 42. | Pritchard KI, Burris HA 3rd, Ito Y, et al. Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2. Clin Breast Cancer, 2013, 13(6):421-432. |
| 43. | Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med, 2001, 344(11):783-792. |
| 44. | Guan Z, Xu B, Desilvio ML, et al. Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer. J Clin Oncol, 2013, 31(16):1947-1953. |
| 45. | Di Leo A, Gomez HL, Aziz Z, et al. Phase Ⅲ, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol, 2008, 26(34):5544-5552. |
| 46. | Moja L, Tagliabue L, Balduzzi S, et al. Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev, 2012, 18(4):CD006243. |
| 47. | Giordano SH, Temin S, Kirshner JJ, et al. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer:American Society of Clinical Oncology clinical practice guideline. J Clin Oncol, 2014, 32(19):2078-2099. |
| 48. | Kaufman B, Mackey JR, Clemens MR, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer:results from the randomized phase Ⅲ TAnDEM study. J Clin Oncol, 2009, 27(33):5529-5537. |
| 49. | Johnston S, Pippen J Jr, Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol, 2009, 27(33):5538-5546. |
| 50. | Carrick S, Parker S, Thornton CE, et al. Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev, 2009, 15(2):CD003372. |
| 51. | Dear RF, McGeechan K, Jenkins MC, et al. Combination versus sequential single agent chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev, 2013, 18(12):CD008792. |
| 52. | Piccart-Gebhart MJ, Burzykowski T, Buyse M, et al. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J Clin Oncol, 2008, 26(12):1980-1986. |
| 53. | Rossari JR, Metzger-Filho O, Paesmans M, et al. Bevacizumab and breast cancer:a meta-analysis of first-line phase Ⅲ studies and a critical reappraisal of available evidence. J Oncol, 2012, 2012:417673. |
| 54. | Gennari A, Stockler M, Puntoni M, et al. Duration of chemotherapy for metastatic breast cancer:a systematic review and meta-analysis of randomized clinical trials. J Clin Oncol, 2011, 29(16):2144-2149. |
| 55. | Ruggiero SL. Bisphosphonate-related osteonecrosis of the jaw:an overview. Ann N Y Acad Sci, 2011, 1218:38-46. |
| 56. | 江澤飛, 陳佳藝, 牛曉輝, 等.乳腺癌骨轉移和骨相關疾病臨床診療專家共識(2014版).中華醫學雜志, 2015, 95(4):241-247. |
| 57. | Barnholtz-Sloan JS, Sloan AE, Davis FG, et al. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol, 2004, 22(14):2865-2872. |
| 58. | Lin NU, Diéras V, Paul D, et al. Multicenter phaseⅡ study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res, 2009, 15(4):1452-1459. |
- 1. Fan L, Strasser-Weippl K, Li JJ, et al. Breast cancer in China. Lancet Oncol, 2014, 15(7):e279-e289.
- 2. NCCN. NCCN clinical practice guidelines in oncology:breast cancer. https://www.nccn.org/professionals/physician_gls/f_guidelines.aspbreast..
- 3. Coates AS, Winer EP, Goldhirsch A, et al. Tailoring therapies-improving the management of early breast cancer:St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol, 2015, 26(8):1533-1546.
- 4. NIH consensus conference. Treatment of early-stage breast cancer. JAMA, 1991, 265(3):391.
- 5. 徐兵河.中國晚期乳腺癌診治專家共識.北京:人民衛生出版社, 2015:1-55.
- 6. 葉蓓, 柳光宇, 陸勁松, 等.常用的乳腺癌血清腫瘤標志物在早期診斷中的應用價值不高.中國癌癥雜志, 2009, 19(10):807-808.
- 7. Rosen EL, Eubank WB, Mankoff DA. FDG PET, PET/CT, and breast cancer imaging. Radiographics, 2007, 27 Suppl 1:S215-S229.
- 8. Eubank WB, Mankoff D, Bhattacharya M, et al. Impact of FDG PET on defining the extent of disease and on the treatment of patients with recurrent or metastatic breast cancer. AJR Am J Roentgenol, 2004, 183(2):479-486.
- 9. Brooks AL. From cell to organism:the need for multiparametric assessment of exposure and biological effects. 2014-12-10. http://www.birpublications.org/doi/abs/10.1259/bjr/78464782..
- 10. Popp HD, Meyer M, Brendel S, et al. Leukocyte DNA damage after reduced and conventional absorbed radiation doses using 3rd generation dual-source CT technology. Eur J Radiol Open, 2016, 3:134-137.
- 11. Theriault RL, Carlson RW, Allred C, et al. Breast cancer, version 3.2013:featured updates to the NCCN guidelines. J Natl Compr Canc Netw, 2013, 11(7):753-760.
- 12. Harbeck N, Scharl A, Thomssen C, et al. AGO recommendations for diagnosis and treatment of patients with advanced and metastatic breast cancer:update 2013. Breast Care (Basel), 2013, 8(3):181-185.
- 13. Danna EA, Sinha P, Gilbert M, et al. Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease. Cancer Res, 2004, 64(6):2205-2211.
- 14. Norton L, Massagué J. Is cancer a disease of self-seeding?. Nat Med, 2006, 12(8):875-878.
- 15. Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med, 2004, 351(8):781-791.
- 16. Arriagada R, Rutqvist LE, Mattsson A, et al. Adequate locoregional treatment for early breast cancer may prevent secondary dissemination. J Clin Oncol, 1995, 13(12):2869-2878.
- 17. Goldie JH, Coldman A. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep, 1980, 63(11-12):1727-1733.
- 18. Fisher B, Gunduz N, Coyle J, et al. Presence of a growth-stimulating factor in serum following primary tumor removal in mice. Cancer Res, 1989, 49(8):1996-2001.
- 19. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin:a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell, 1994, 79(2):315-328.
- 20. Gunduz N, Fisher B, Saffer EA. Effect of surgical removal on the growth and kinetics of residual tumor. Cancer Res, 1979, 39(10):3861-3865.
- 21. Salo M. Effects of anaesthesia and surgery on the immune response. Acta Anaesthesiol Scand, 1992, 36(3):201-220.
- 22. Dominici L, Najita J, Hughes M, et al. Surgery of the primary tumor does not improve survival in stage Ⅳ breast cancer. Breast Cancer Res Treat, 2011, 129(2):459-465.
- 23. Neuman HB, Morrogh M, Gonen M, et al. Stage Ⅳ breast cancer in the era of targeted therapy:does surgery of the primary tumor matter?. Cancer, 2010, 116(5):1226-1233.
- 24. Rapiti E, Verkooijen HM, Vlastos G, et al. Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis. J Clin Oncol, 2006, 24(18):2743-2749.
- 25. Hartmann S, Reimer T, Gerber B, et al. Primary metastatic breast cancer:the impact of locoregional therapy. Breast Care (Basel), 2014, 9(1):23-28.
- 26. Harris E, Barry M, Kell MR. Meta-analysis to determine if surgical resection of the primary tumour in the setting of stage Ⅳ breast cancer impacts on survival. Ann Surg Oncol, 2013, 20(9):2828-2834.
- 27. Clinicaltrials. https://clinicaltrials.gov/ct2/show/NCT00193778..
- 28. Clinicaltrials. https://clinicaltrials.gov/ct2/show/NCT00557986?term=NCT00557986&rank=1..
- 29. Clinicaltrials. https://clinicaltrials.gov/ct2/show/NCT01242800?term=NCT01242800&rank=1..
- 30. Clinicaltrials. https://clinicaltrials.gov/ct2/show/NCT01392586?term=NCT01392586&rank=1..
- 31. Clinicaltrials. https://clinicaltrials.gov/ct2/show/NCT01015625?term=NCT01015625&rank=1..
- 32. Shien T, Nakamura K, Shibata T, et al. A randomized controlled trial comparing primary tumour resection plus systemic therapy with systemic therapy alone in metastatic breast cancer (PRIM-BC):Japan Clinical Oncology Group Study JCOG1017. Jpn J Clin Oncol, 2012, 42(10):970-973.
- 33. Badwe R, Hawaldar R, Nair N, et al. Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer:an open-label randomised controlled trial. Lancet Oncol, 2015, 16(13):1380-1388.
- 34. King TA, Lyman JP, Gonen M, et al. Prognostic impact of 21-gene recurrence score in patients with stage Ⅳ breast cancer:TBCRC 013. J Clin Oncol, 2016, 34(20):2359-2365.
- 35. ASC University. A randomized controlled trial evaluating resection of the primary breast tumor in women presenting with de novo stage Ⅳ breast cancer:Turkish Study (Protocol MF07-01). http://meeting-library.asco.org/content/170268-176..
- 36. Headon H, Wazir U, Kasem A, et al. Surgical treatment of the primary tumour improves the overall survival in patients with metastatic breast cancer:a systematic review and meta-analysis. Mol Clin Oncol, 2016, 4(5):863-867.
- 37. Niveen A, Abo-Touk, Amir A, et al. The benefit of locoregional surgical intervention in metastatic breast cancer at initial presentation. Cancer Res J, 2016, 4(2):32-36.
- 38. 江澤飛, 李健斌.精準醫學時代乳腺外科十個熱點問題思考.中華普外科手術學雜志:電子版, 2016, 10(3):192-196.
- 39. Viale G, Regan MM, Maiorano E, et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer:BIG 1-98. J Clin Oncol, 2007, 25(25):3846-3852.
- 40. Allred DC. Commentary:hormone receptor testing in breast cancer:a distress signal from Canada. Oncologist, 2008, 13(11):1134-1136.
- 41. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med, 2012, 366(6):520-529.
- 42. Pritchard KI, Burris HA 3rd, Ito Y, et al. Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2. Clin Breast Cancer, 2013, 13(6):421-432.
- 43. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med, 2001, 344(11):783-792.
- 44. Guan Z, Xu B, Desilvio ML, et al. Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer. J Clin Oncol, 2013, 31(16):1947-1953.
- 45. Di Leo A, Gomez HL, Aziz Z, et al. Phase Ⅲ, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol, 2008, 26(34):5544-5552.
- 46. Moja L, Tagliabue L, Balduzzi S, et al. Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev, 2012, 18(4):CD006243.
- 47. Giordano SH, Temin S, Kirshner JJ, et al. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer:American Society of Clinical Oncology clinical practice guideline. J Clin Oncol, 2014, 32(19):2078-2099.
- 48. Kaufman B, Mackey JR, Clemens MR, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer:results from the randomized phase Ⅲ TAnDEM study. J Clin Oncol, 2009, 27(33):5529-5537.
- 49. Johnston S, Pippen J Jr, Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol, 2009, 27(33):5538-5546.
- 50. Carrick S, Parker S, Thornton CE, et al. Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev, 2009, 15(2):CD003372.
- 51. Dear RF, McGeechan K, Jenkins MC, et al. Combination versus sequential single agent chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev, 2013, 18(12):CD008792.
- 52. Piccart-Gebhart MJ, Burzykowski T, Buyse M, et al. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J Clin Oncol, 2008, 26(12):1980-1986.
- 53. Rossari JR, Metzger-Filho O, Paesmans M, et al. Bevacizumab and breast cancer:a meta-analysis of first-line phase Ⅲ studies and a critical reappraisal of available evidence. J Oncol, 2012, 2012:417673.
- 54. Gennari A, Stockler M, Puntoni M, et al. Duration of chemotherapy for metastatic breast cancer:a systematic review and meta-analysis of randomized clinical trials. J Clin Oncol, 2011, 29(16):2144-2149.
- 55. Ruggiero SL. Bisphosphonate-related osteonecrosis of the jaw:an overview. Ann N Y Acad Sci, 2011, 1218:38-46.
- 56. 江澤飛, 陳佳藝, 牛曉輝, 等.乳腺癌骨轉移和骨相關疾病臨床診療專家共識(2014版).中華醫學雜志, 2015, 95(4):241-247.
- 57. Barnholtz-Sloan JS, Sloan AE, Davis FG, et al. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol, 2004, 22(14):2865-2872.
- 58. Lin NU, Diéras V, Paul D, et al. Multicenter phaseⅡ study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res, 2009, 15(4):1452-1459.
-
Next Article
乳腺癌同側鎖骨上淋巴結轉移治療的共識與爭議